Isopropyl-n-butyl-oxalat | 26404-32-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Isopropyl-n-butyl-oxalat
• 英文别名: 1-O-butyl 2-O-propan-2-yl oxalate
• CAS: 26404-32-0
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: PHYOZOXAHMIUKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Isopropyl-n-butyl-oxalat 在 五氯化磷 作用下， 生成 Dichlor-butyloxy-essigsaeure-isopropylester
  参考文献：
  名称：

  Ivashchenko,Ya.N.; Moshchitskii,S.D., Journal of general chemistry of the USSR, 1964, vol. 34, p. 610 - 613

  摘要：

  DOI：
• 作为产物：
  描述：

  草酸二异丙酯 、 正丁醇 在 copper(l) chloride 作用下， 生成 Isopropyl-n-butyl-oxalat
  参考文献：
  名称：

  Ivashchenko,Ya.N.; Moshchitskii,S.D., Soviet progress in chemistry, 1969, vol. 35, # 11, p. 59 - 60

  摘要：

  DOI：

文献信息

• Novel amide derivatives
  申请人：——

  公开号：US20040204369A1

  公开（公告）日：2004-10-14

  This invention relates to compounds which are represented by the general formula [I] 1 [in which A stands for a group of the following formula [a o ] or [b o ] 2 Ar 1 , Ar 2 and Ar 3 stand for optionally substituted phenyl; k stands for 0 or 1; m, n and s stand for 0, 1 or 2; R 1 stands for hydrogen or optionally substituted lower alkyl; R 2 , R 3 , R 4 and R 5 either stand for hydrogen or optionally substituted lower alkyl, or R 2 and R 3 , or R 4 and R 5 together stand for trimethylene and the like; R 60 stands for hydrogen, alkyl, or the like; R 61 and R 71 either stand for alkyl and the like, or together stand for trimethylene and the like; X stands for carbonyl or methylene; Y stands for nitrogen or methine; and Q − stands for anion], and the like. The compounds of the invention exhibit selective antagonism to muscarinic M 3 receptors, and therefore are useful as safe and effective agents showing little side effect, for treating diseases of the respiratory, urinary and digestive systems.

  本发明涉及由一般公式[I]1表示的化合物，其中A代表以下式[ao]或[bo]2Ar1的基团，Ar2和Ar3代表可选取代的苯基；k代表0或1；m、n和s代表0、1或2；R1代表氢或可选取代的低碳基；R2、R3、R4和R5要么代表氢或可选取代的低碳基，要么R2和R3，或者R4和R5一起代表三亚甲基等；R60代表氢、烷基或类似物；R61和R71要么代表烷基等，要么一起代表三亚甲基等；X代表羰基或亚甲基；Y代表氮或亚甲基；Q^-代表阴离子等。本发明的化合物表现出选择性的M3胆碱能受体拮抗作用，因此可用作治疗呼吸、泌尿和消化系统疾病的安全有效药物，副作用小。
• Imidazopyridine compounds and processes for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0268989A1

  公开（公告）日：1988-06-01

  An imidazopyridine compound of the formula : wherein R' is lower alkynyl, lower alkynyloxy(lower)alkyl or N,N-di(lower)alkylamino(lower)alkynyl, R2 is lower alkyl, R3 is ar(lower)alkyl substituted by one or more substituent(s) selected from cyano, trihalo(lower)alkyl, carbamoyl, protected amino, carboxy, protected carboxy, hydroxy, hydroxy(lower)alkyl, protected hydroxy-(lower)alkyl, protected hydroxy and protected amino(lower)alkyl or ar(lower)alkyl substituted by lower alkyl and one additional substituent selected from hydroxy(lower)alkyl, amino, N-lower alkyl-N-protected amino, protected amino and lower alkylamino, and R4 is hydrogen or lower alkyl, and a pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them. The invention also comprises intermediates of the formula and of the formula

  式中的咪唑吡啶化合物 其中 R' 是低级炔基、低级炔氧基（低级）烷基或 N,N-二（低级）烷基氨基（低级）炔基、 R2 是低级烷基 R3 是被一个或多个选自氰基、三卤代（低级）烷基、氨基甲酰基、受保护氨基、羧基、受保护羧基、羟基、羟基（低级）烷基、受保护羟基（低级）烷基、受保护羟基和受保护氨基（低级）烷基的取代基取代的 ar（低级）烷基，或被低级烷基和一个选自羟基（低级）烷基、氨基、N-低级烷基-N-受保护氨基、受保护氨基和低级烷基氨基的取代基取代的 ar（低级）烷基，以及 R4 是氢或低级烷基、 及其药学上可接受的盐、其制备工艺和包含它们的药物组合物。本发明还包括式 和式
• MEDICINAL COMPOSITIONS RETARDED IN THE DISCOLORATION OF PHENOLIC HYDROXYL COMPOUNDS
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1151750A1

  公开（公告）日：2001-11-07

  Coloring change of a pharmaceutical composition containing a compound having a phenolic hydroxyl group, such as an anti-inflammatory agent or an antioxidant having a phenolic hydroxyl group or the compound (I) can be controlled by including an acid. The present invention provides a pharmaceutical composition containing a compound having a phenolic hydroxyl group with coloring change being controlled.

  含有具有酚羟基的化合物（如具有酚羟基的消炎剂或抗氧化剂或化合物 (I)）的药物组合物的着色变化可通过加入酸来控制。本发明提供了一种含有具有酚羟基的化合物的药物组合物，其着色变化可控。
• NOVEL QUINAZOLINE DERIVATIVES
  申请人：Japan Energy Corporation

  公开号：EP1229025A1

  公开（公告）日：2002-08-07

  Quinazoline derivatives represented by the general formula (1) or a pharmaceutically acceptable salt thereof in said formula R1 is nitro or halogen; R2 and R4 are each hydrogen, C1-4 alkyl, carboxyl, or C2-5 alkoxycarbonyl; R3 is hydrogen, amino, optionally substituted C1-4 alkyl, C1-4 alkanoyl, or C2-5 alkoxycarbonyl; W is carbon or nitrogen; and m is 0 to 2.

  通式（1）所代表的喹唑啉衍生物或其药学上可接受的盐，所述式中 R1 为硝基或卤素；R2 和 R4 分别为氢、C1-4 烷基、羧基或 C2-5 烷氧基羰基；R3 为氢、氨基、任选取代的 C1-4 烷基、C1-4 烷酰基或 C2-5 烷氧基羰基；W 为碳或氮；m 为 0 至 2。
• NOVEL AMIDE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1213281B1

  公开（公告）日：2004-02-18